TL;DR: BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice, studied in rodent models for its effects on tissue repair, angiogenesis, and cytoprotection. The research base is substantial at the preclinical level, with consistent findings across tendon, muscle, gut, and CNS injury models, but human clinical evidence remains very limited. BPC-157 is not FDA approved, not approved for human use, and is classified by WADA as a prohibited non-approved substance.
Research-Use Disclaimer: This article is for educational and research reference purposes only. BPC-157 is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.
What Is BPC-157? Definition and Origins
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protein isolated in human gastric juice. Its amino acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Unlike many research peptides that are fragments of hormones or growth factors, BPC-157 is a partial sequence of the body’s own gastric protein BPC, selected and synthesized for stability and study.
The compound is described in the research literature as “stable in human gastric juice”, meaning it resists degradation in an acidic environment, which distinguishes it from most peptides and has made it a subject of ongoing investigation by researchers including Predrag Sikiric and colleagues at the University of Zagreb, whose laboratory has produced the majority of published BPC-157 studies over three decades.
What Mechanisms Has BPC-157 Research Documented?
BPC-157’s preclinical research profile spans several mechanistic pathways. The compound does not appear to operate through a single receptor target; rather, peer-reviewed reviews describe it as a “pleiotropic” agent, one documented to interact with multiple biological systems simultaneously. The most consistently cited mechanisms in the literature are summarized below.
1. VEGF Upregulation and Angiogenesis Modulation
A 2009 study by Brcic et al., published in the Journal of Physiology and Pharmacology, investigated BPC-157’s angiogenic activity in crushed muscle and transected muscle-tendon rodent models. The study found that BPC-157 did not produce direct angiogenic effects in cell cultures alone, but immunohistochemical analysis showed upregulated VEGF expression and increased CD34 and Factor VIII markers in BPC-157-treated animals, consistent with modulated angiogenesis in the context of active tissue injury.
A 2018 review by Seiwerth et al. in Current Pharmaceutical Design further examined BPC-157 against standard angiogenic growth factors, drawing on findings from tendon, ligament, muscle, bone, and gastrointestinal healing models to characterize BPC-157 as a context-sensitive angiogenic modulator rather than a direct growth-factor mimic.
2. Nitric Oxide (NO) System Interaction
A 2014 review by Sikiric et al. in Current Pharmaceutical Design systematically examined the relationship between BPC-157 and the nitric oxide system, describing BPC-157 as closely participating in a “homeostatic healing response” of the NO system. The review documented interactions with both NOS (nitric oxide synthase) pathways and downstream NO-mediated effects in preclinical injury and cytoprotection models. This NO-system connection is one of the mechanisms proposed to explain BPC-157’s apparent cytoprotective properties across multiple tissue types.
3. Tendon and Musculoskeletal Repair
Among BPC-157’s most-studied research contexts is its behavior in rodent musculoskeletal injury models. A 2008 study by Krivic et al. in Inflammation Research compared BPC-157 to methylprednisolone in a rat model of Achilles tendon-to-bone transection, finding that BPC-157-treated animals demonstrated earlier functional recovery compared to controls, with the effect preceding collagen remodeling. A 2022 review by Staresinic et al. in Biomedicines extended this to striated, smooth, and cardiac muscle, documenting cytoprotective effects attributed to BPC-157 therapy in rodent models.
4. Wound Healing and Gastrointestinal Cytoprotection
A 2021 review by Seiwerth et al. in Frontiers in Pharmacology noted that BPC-157 was previously employed in two human trials for ulcerative colitis and multiple sclerosis with no reported toxicity, and reviewed wound-healing evidence across skin, cornea, tendon, ligament, muscle, and gastrointestinal tissue in preclinical models. A 2020 review by Sikiric et al. focused on fistula-healing models, documenting accelerated fistula closure across several gastrointestinal presentations in rodents.
5. Central Nervous System and Gut-Brain Axis
More recent research has explored BPC-157’s effects in neurological contexts. A 2022 paper by Vukojevic et al. in Neural Regeneration Research reviewed BPC-157’s documented effects in rodent models of CNS injury, including gut-brain axis implications, and a 2024 paper by Sikiric et al. in Pharmaceuticals reviewed proposed relationships with dopaminergic, serotonergic, and GABAergic systems in preclinical models. A separate 2023 review proposed a “collateral pathway activation” framework to explain the compound’s documented multi-system effects in rodent models.
What Is BPC-157’s Evidence Tier? An Honest Assessment
Researchers and science communicators who discuss BPC-157 should accurately represent the state of the evidence. The following summarizes the landscape as documented in published literature:
| Evidence Level | Status for BPC-157 (as of 2026) |
|---|---|
| Human randomized controlled trials | Not available for tissue repair; two small early-phase trials cited for GI indications only |
| Peer-reviewed animal model studies | Substantial, multiple independent rodent studies across several tissue types |
| In vitro / cell culture evidence | Present but mixed; some mechanisms not replicated in cell culture alone |
| FDA approval status | Not approved for any human use |
| WADA status | Prohibited, Section S0 (Non-Approved Substances) |
The critical limitation to state plainly: animal models, even well-designed ones, do not guarantee that effects translate to humans. Rodent tissue biology, injury models, and pharmacokinetics differ meaningfully from human physiology. The BPC-157 research base is notable for its breadth and internal consistency at the preclinical level, but the absence of large human RCTs means its efficacy and safety profile in humans remains scientifically unestablished.
What Is BPC-157’s Regulatory Status?
FDA (United States)
BPC-157 is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. In 2023–2024, the FDA placed BPC-157 in a category that restricts compounding pharmacies from dispensing it, citing its unapproved status. Researchers should consult current FDA guidance directly.
WADA (World Anti-Doping Agency)
BPC-157 is explicitly listed under Section S0: Non-Approved Substances on the WADA Prohibited List. S0 applies to any pharmacological substance not currently approved by any governmental regulatory authority for human therapeutic use. Athletes subject to WADA rules are prohibited from using it in any context.
Frequently Asked Questions About BPC-157
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any therapeutic use in humans. It is classified as a research compound, studied predominantly in preclinical rodent models. It has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement in the United States.
What does the BPC-157 research actually show?
The peer-reviewed literature, primarily rodent and in vitro, documents BPC-157’s association with upregulated VEGF expression, modulation of the nitric oxide system, and accelerated tissue repair in injury models involving tendon, muscle, gut, and bone. Human clinical data is extremely limited; no large placebo-controlled human RCTs for tissue repair have been published as of 2026.
What is BPC-157’s evidence tier?
BPC-157 is a Tier 2 compound in the Legendary Labz framework: multiple peer-reviewed animal model studies with consistent findings, but lacking the human RCT evidence required for Tier 1 classification. Full evidence-tier methodology is documented in the guide.
Where is BPC-157 on the WADA Prohibited List?
The WADA Prohibited List places BPC-157 under Section S0: Non-Approved Substances, covering any pharmacological substance not approved by a regulatory authority for human therapeutic use. The prohibition applies in- and out-of-competition.
Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.